OVID THERAPEUTICS DL-,001

At the Cantor conference Ovid Therapeutics presented its two‑pillar strategy centered on the KCC2 program (OV4071) and the epilepsy pipeline (notably OV329), and views KCC2 as the main long‑term value driver if early human data confirm preclinical results. OV4071 is in phase I; a ketamine challenge and several biomarker studies are intended to link earlier animal data with human data. OV329 is being positioned to differentiate in focal-onset and pediatric epilepsies; proof‑of‑concept data and a phase II are planned for 2024/2025. Ovid also retains rights to milestone/license payments from Soticlestat, which represents additional upside without development risk. » More on de.investing.com

Ovid Therapeutics appointed Kevin Norrett as chief business officer to lead business development and strategic partnerships. Charles Carter was promoted to CFO, succeeding Jeffrey Rona who will remain a long-term advisor through 2027, and Victoria Fort was promoted to chief strategy officer. The company reported Q1 EPS of (12c), said development programs are on track, and expects to be well capitalized into 2029. » More on finance.yahoo.com

Ovid Therapeutics brings in Kevin Norrett as chief business officer to lead business and corporate development and strategic partnerships. Charles Carter was promoted to chief financial officer; Jeffrey Rona will remain on board as an advisor through 2027. Eliseo Salinas joins as executive R&D advisor and Victoria Fort was promoted to chief strategy officer; Fort led financing rounds that secure the company’s cash runway through 2029. The company is developing, among others, OV329 for treatment-resistant focal-onset seizures and OV4071 for central nervous system disorders. » More on de.investing.com